RXQ Compounding Methylprednisolone Acetate Injection Recall: Sterility Risk
RXQ Compounding recalls methylprednisolone acetate injection vials due to potential contamination from improper autoclave sterilization. Affected lots produced in Athens, OH with specific NDC and expiration dates.
Use caution until it’s fixed
Lack of Assurance of Sterility; autoclave parameters were not correct for one of two autoclaves used to sterilize the product.
Contact the company
What happened, in plain English
RXQ Compounding is recalling methylprednisolone acetate injection vials that may not be sterile due to improper autoclave sterilization. This could lead to infections if used improperly. Read more at govinfonow.com/recall/41169-rxq-compounding-methylprednisolone-acetate-injection-recall-sterility-risk.
Source Summary by GovInfoNow · govinfonow.com/recall/41169-rxq-compounding-methylprednisolone-acetate-injection-recall-sterility-risk · Updated October 7, 2026 · FDA enforcement record: FDA #D-0012-2018
Cite this page
“RXQ Compounding Methylprednisolone Acetate Injection Recall: Sterility Risk.” GovInfoNow, updated October 7, 2026. https://govinfonow.com/recall/41169-rxq-compounding-methylprednisolone-acetate-injection-recall-sterility-risk. Based on FDA recall #D-0012-2018 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0012-2018%22&limit=1).
Why it’s dangerous
The product was sterilized using incorrect autoclave settings for one of two autoclaves, which could result in contamination. This poses a risk of infection if the medication is used without proper sterility.
Who’s affected
Patients receiving this medication from RXQ Compounding in Athens, OH are affected. Those with specific NDC 70731-0936-10 and lot 04252017@1 are most at risk.
How to tell if you have this one
Check for the NDC number 70731-0936-10 and lot number 04252017@1 on the vial label. The product was manufactured in Athens, OH and expires May 9, 2018.
- Brand
RXQ Compounding- Category
Drug
What to do — step by step
Check Vial Label
Look for NDC 70731-0936-10 and lot number 04252017@1 on the vial label.
Where it went and when
Where it was distributed
Distributed in 6 states.
FDA distribution: “TX, LA, PA, MA, FL, and OH” States read from FDA’s own wording; “not listed” means the notice does not name it.
States: Florida, Louisiana, Massachusetts, Ohio, Pennsylvania, Texas.
Recall timeline
FDA terminated this recall 2 months after the firm started it.
- Firm started the recall
- FDA classified it Class II
- Published in FDA’s Enforcement Report
- FDA terminated the recall
Dates from the agency record only; steps without a date are left out.
Similar recalls
Latest drug recalls
Keep exploring
Where this comes from
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
- Official source: FDA Recall #D-0012-2018 (September 25, 2017) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0012-2018 to see it in context.
- Plain-language summary written by qwen3:4b on October 7, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
- GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.